arrow
C

Claire-Anne Siegrist

University of Geneva
H指数:73
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-AG-ZEBOV-GP in a sub-Saharan African paediatric population: A randomised controlled, open-label trial in children aged 1-12 years living in Lambaréné, Gabon

载体埃博拉疫苗rvsv-ag-zebov-gp在撒哈拉以南非洲儿童人群中的复制,安全性和免疫原性: 居住在加蓬lamba é n é 的1-12岁儿童的随机对照,开放标签试验

2024-10-010
OAAI
Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability
2023-12-013
OA
Baseline gene signatures of reactogenicity to Ebola vaccination: a machine learning approach across multiple cohorts
2023-11-081
OAAI
Antibody response in children with multisystem inflammatory syndrome related to COVID-19 (MIS-C) compared to children with uncomplicated COVID-19

与无并发症新型冠状病毒肺炎儿童相比,与新型冠状病毒肺炎相关的多系统炎症综合征 (mis-c) 儿童的抗体反应

2023-03-1510
OAAI
Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs
2022-07-0453
OAAI
Fitness of B-Cell Responses to SARS-CoV-2 WT and Variants Up to One Year After Mild COVID-19-A Comprehensive Analysis
2022-05-020
OAAI
Robust innate responses to SARS-CoV-2 in children resolve faster than in adults without compromising adaptive immunity
2021-10-0160
OAAI
SARS-CoV-2 infection as a trigger of humoral response against apolipoprotein A-1
2021-08-0410
OA
Clinical, virologic and immunologic features of a mild case of SARS-CoV-2 reinfection

轻度SARS-CoV-2再感染的临床,病毒学和免疫学特征

2021-05-0116
OAAI
Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study
2021-05-01107
OAAI